Screener
BridgeBio Pharma BBIO Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Property and equipment, net | 4,941 | 5,366 |
| Operating lease right-of-use assets | 17,226 | 8,149 |
| Intangible assets, net | 27,359 | 28,077 |
| Other assets | 18,620 | 16,712 |
| Total assets | $1,370,981 | $936,025 |
| Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $29,058 | $36,228 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's other non-current assets?
- BridgeBio Pharma (BBIO) reported other non-current assets of $18.62M in Q1 2026.
- How has BridgeBio Pharma's other non-current assets changed year-over-year?
- BridgeBio Pharma's other non-current assets increased by 12.1% year-over-year, from $16.61M to $18.62M.
- What is the long-term trend for BridgeBio Pharma's other non-current assets?
- Over 5 years (2020 to 2025), BridgeBio Pharma's other non-current assets has grown at a -6.9% compound annual growth rate (CAGR), from $23.93M to $16.71M.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about BridgeBio Pharma's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude